The dilutive offering at a 2.8% discount to the current price (assuming $3.60 close) adds overhang. Monitor for further dilution if the shelf is tapped again. The company's cash runway extends but at the cost of shareholder value.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 5 $4.14entry
- T+1 · 5mo ago +4.59%α +4.36% · $4.33
- T+5 · 5mo ago −7.25%α −7.82% · $3.84
- T+20 · 4mo ago −4.71%α −6.57% · $3.95
- T+60 · 3mo ago −15.94%α −19.94% · $3.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds. The proceeds will be used for working capital and general corporate purposes to support the company's clinical-stage pipeline for CNS disorders.
Key Financial Metrics
Key Facts
- Closed underwritten public offering of common stock at $3.50 per share
- Gross proceeds of approximately $22.3 million
- Proceeds to be used for working capital and general corporate purposes
- BTIG and Lucid Capital Markets acted as bookrunners
- Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)
Financial Impact
Dilution of approximately 6.37 million shares at $3.50 per share, representing about 15% of pre-offering shares outstanding (based on $147M market cap / $3.50 = 42M shares pre-offering). Gross proceeds of $22.3 million.
Risk Factors
- Further dilution from remaining shelf capacity
- Clinical-stage pipeline with no approved products; regulatory and commercial risks
- Potential for additional capital raises given operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307137 |
Track record
22 reports on NRXP
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers